Welcome to our dedicated page for Synlogic news (Ticker: SYBX), a resource for investors and traders seeking the latest updates and insights on Synlogic stock.
Synlogic, Inc. (SYBX) pioneers synthetic biology solutions targeting rare metabolic disorders through its innovative engineered probiotics. This dedicated news hub provides investors and industry observers with essential updates on clinical developments, regulatory milestones, and strategic partnerships.
Access timely reports on Synlogic's synthetic biotics platform progress, including trial results for phenylketonuria (PKU) therapies and microbiome research breakthroughs. Our curated collection features earnings announcements, patent filings, and scientific collaborations that shape the company's trajectory in biopharmaceutical innovation.
Key updates include FDA designations, partnership agreements with leading research institutions, and advancements in oral therapeutic delivery systems. Bookmark this page for streamlined access to verified information about Synlogic's novel approach to metabolic disease treatment.
Synlogic, Inc. (SYBX) will release its second quarter 2021 financial results on August 12, 2021, prior to market opening. The release will be followed by a conference call at 8:30 am ET, accessible via telephone and webcast. CEO Aoife Brennan will also present at the BTIG Virtual Biotechnology Conference on August 10, 2021. Synlogic focuses on synthetic biology to develop therapeutics for metabolic disorders and is advancing its pipeline in immunology and oncology.
Synlogic, Inc. (Nasdaq: SYBX) has published two significant papers in Nature Metabolism and Communications Biology detailing findings from the first-in-human study of SYNB1618, a Synthetic Biotic™ medicine for treating Phenylketonuria (PKU). The studies indicate SYNB1618 is safe, well-tolerated, and effectively lowers toxic phenylalanine levels in the GI tract of healthy volunteers and PKU patients. Synlogic anticipates proof-of-concept results for SYNB1618 in late 2021 as part of its ongoing Phase 2 clinical trial.
Synlogic, Inc. (Nasdaq: SYBX) announced the initiation of a Phase 1 clinical trial for SYNB1934, a Synthetic Biotic medicine aimed at treating Phenylketonuria (PKU). This new candidate shows a more than 2-fold improvement in phenylalanine (Phe) breakdown compared to its predecessor, SYNB1618. The trial will evaluate the safety, tolerability, and Phe consumption activity of SYNB1934, with results expected by the end of 2021. Synlogic aims to support PKU patients by providing effective treatment options, particularly for those not benefiting from existing therapies.
Synlogic, Inc. (SYBX) has entered a research collaboration agreement with Roche to develop a novel Synthetic Biotic medicine for inflammatory bowel disease (IBD). This partnership aims to address an undisclosed target in IBD, reflecting Synlogic's commitment to innovative treatments. Roche will have an exclusive option for further development and commercialization following the research period. Synlogic's pipeline includes treatments for metabolic disorders, emphasizing the company's focus on addressing unmet patient needs in inflammation.
Synlogic, a clinical-stage company, presented at the SEED conference on SYNB8802 and SYNB1934, investigational Synthetic Biotic medicines targeting Enteric Hyperoxaluria and Phenylketonuria (PKU), respectively. SYNB1934 shows over a 2-fold improvement in metabolizing phenylalanine compared to SYNB1618, while SYNB8802 demonstrates strain activity throughout the GI tract. Both treatments aim to address unmet medical needs, as no approved options currently exist for these conditions. The presentations highlight Synlogic's commitment to using synthetic biology for innovative therapies.
Synlogic, Inc. (Nasdaq: SYBX) has announced its 2021 Annual General Meeting of Stockholders will occur on June 10, 2021, at 9:00 am ET, via virtual format.
Stockholders of record as of April 13, 2021, can access the meeting through this link starting at 8:45 am ET. Synlogic encourages stockholders to vote and submit proxies beforehand. The company focuses on developing Synthetic Biotic medicines for metabolic disorders and has a proprietary pipeline targeting additional diseases.
Synlogic, Inc. (Nasdaq: SYBX) announced that President and CEO Aoife Brennan will present at the Jefferies Virtual Healthcare Conference on June 1, 2021, at 1:30 pm. This virtual event will feature a Fireside Chat, and a live webcast will be accessible through the company's website, with an archived version available for 30 days post-event. Synlogic leverages synthetic biology to develop innovative therapeutics for metabolic disorders and is expanding its portfolio in immunology and oncology.
On May 23, 2021, Synlogic, Inc. (SYBX) presented data on its Synthetic Biotic medicines aimed at treating inflammatory bowel disease (IBD) during Digestive Disease Week. The presentation, delivered by Mylene Perreault, showcased an investigational program focusing on a novel IL-22-secreting Synthetic Biotic. Synlogic aims to leverage synthetic biology to innovate treatments for various diseases, with a proprietary pipeline also targeting metabolic disorders like Phenylketonuria. The event was held virtually from May 21-23, 2021.
Synlogic, Inc. (Nasdaq: SYBX) reported Q1 2021 results, highlighting its progress in developing Synthetic Biotic medicines. The company remains on track with its SynPheny-1 Phase 2 trial for SYNB1618, targeting Phenylketonuria (PKU), and anticipates data in H2 2021. SYNB8802, aimed at Enteric Hyperoxaluria, demonstrated a 28.6% reduction in urinary oxalate in early studies. Synlogic completed a $32.6 million public offering, bringing cash reserves to $127 million. The firm expects to sustain operations through mid-2023 with its current cash flow and strategic partnerships.
Synlogic, Inc. (SYBX), a clinical-stage company focusing on synthetic biology, will announce its first quarter 2021 financial results on May 13, 2021, prior to market opening. A conference call will follow at 8:30 am ET to discuss these results and provide a corporate update. Participants can join via a provided dial-in number or through a webcast. The company specializes in developing Synthetic Biotic therapeutics for metabolic disorders.
